SHIRE PHARMACEUTICALS LLC for SHIRE PHARMACEUTICALS LLC
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing
| Lobbyist | Covered position, as disclosed |
|---|---|
| ENGEL BURNS | — |
| JED PERRY | — |
Pharmacy PHA
ADHD Awareness *Drug Values -DEA processes and re-exportation -FDA Funding -Medicaid rare disease patient access to therapy Patient access to therapy, including Medicaid, Medicare, and insurance. -Orphan Drug Act regulations -Expanded Access -Rare Disease awareness -Right to Try legislation (S. 204, H.R. 878, and H.R. 2368) -Newborn Screening
| Lobbyist | Covered position, as disclosed |
|---|---|
| JED PERRY | — |
Taxation/Internal Revenue Code TAX
Orphan drug tax credit HR 1: An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018 (Tax Cuts and Jobs Act)
| Lobbyist | Covered position, as disclosed |
|---|---|
| JED PERRY | — |
Medicare/Medicaid MMM
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - Bipartisan Budget Act - HR 1892 - Medicare Part D
| Lobbyist | Covered position, as disclosed |
|---|---|
| ENGEL BURNS | — |
| JED PERRY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.